IN2014MN02029A - - Google Patents

Info

Publication number
IN2014MN02029A
IN2014MN02029A IN2029MUN2014A IN2014MN02029A IN 2014MN02029 A IN2014MN02029 A IN 2014MN02029A IN 2029MUN2014 A IN2029MUN2014 A IN 2029MUN2014A IN 2014MN02029 A IN2014MN02029 A IN 2014MN02029A
Authority
IN
India
Prior art keywords
orally disintegrating
disintegrating tablet
33provided
palatable
mouth
Prior art date
Application number
Other languages
English (en)
Inventor
Gaku Sekiguchi
Ryoichi Hayakawa
Yoshihiro Hara
Original Assignee
Daiichi Sankyo Companyltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Companyltd filed Critical Daiichi Sankyo Companyltd
Publication of IN2014MN02029A publication Critical patent/IN2014MN02029A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN2029MUN2014 2012-04-24 2013-04-23 IN2014MN02029A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012098770 2012-04-24
PCT/JP2013/061936 WO2013161823A1 (ja) 2012-04-24 2013-04-23 口腔内崩壊錠及びその製造方法

Publications (1)

Publication Number Publication Date
IN2014MN02029A true IN2014MN02029A (es) 2015-08-14

Family

ID=49483132

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2029MUN2014 IN2014MN02029A (es) 2012-04-24 2013-04-23

Country Status (12)

Country Link
US (1) US9827200B2 (es)
EP (1) EP2842549B1 (es)
JP (4) JP6066351B2 (es)
KR (1) KR101943686B1 (es)
CN (2) CN106913553A (es)
BR (1) BR112014026292B1 (es)
CA (1) CA2870868C (es)
ES (1) ES2694224T3 (es)
HK (1) HK1206983A1 (es)
IN (1) IN2014MN02029A (es)
TW (1) TWI572371B (es)
WO (1) WO2013161823A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2690685C2 (ru) * 2014-10-03 2019-06-05 Новартис Аг Фармацевтические композиции, содержащие алпелисиб
JP5827428B1 (ja) * 2015-01-15 2015-12-02 日新製薬株式会社 テルミサルタン含有錠剤
JP2016141630A (ja) * 2015-01-30 2016-08-08 富士フイルム株式会社 口腔内崩壊錠
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CN108066304B (zh) * 2016-11-16 2022-09-16 深圳万和制药有限公司 具有缓释性能的坦索罗辛口腔崩解片组合物
TWI812602B (zh) 2016-12-01 2023-08-21 日商第一三共股份有限公司 含二胺衍生物之口腔崩散錠及其製造方法
JP7009288B2 (ja) * 2017-05-18 2022-01-25 エルメッド株式会社 湿製錠剤の製造方法及び湿製錠剤の品質向上方法
JP7023186B2 (ja) * 2017-05-29 2022-02-21 第一三共株式会社 認知症治療薬を含有する口腔内崩壊性錠剤
JP7182356B2 (ja) * 2017-07-05 2022-12-02 日本ケミファ株式会社 口腔内崩壊錠及びその製造方法
JP7198575B2 (ja) * 2017-07-11 2023-01-04 キョーリンリメディオ株式会社 メマンチン塩酸塩含有口腔内崩壊錠
JP7148319B2 (ja) * 2017-08-17 2022-10-05 第一三共株式会社 プラスグレルを含む口腔内崩壊錠
JP7360949B2 (ja) * 2017-12-26 2023-10-13 東和薬品株式会社 環状口腔内崩壊錠
WO2019146642A1 (ja) * 2018-01-24 2019-08-01 大原薬品工業株式会社 γ－アミノ酪酸誘導体含有錠剤の化学的安定性を改善する方法
CN110613691A (zh) * 2018-06-19 2019-12-27 北京万全德众医药生物技术有限公司 一种含有peg-dspe-盐酸美金刚复合物的口崩片
TWI826474B (zh) 2018-06-27 2023-12-21 日商第一三共股份有限公司 包含二胺衍生物之顆粒劑、以及其用途及製造方法
CN109512790A (zh) * 2018-12-28 2019-03-26 金日制药（中国）有限公司 一种口腔崩解片的处方及制备工艺
WO2021095092A1 (ja) * 2019-11-11 2021-05-20 大塚製薬株式会社 口腔内崩壊錠
US20230255907A1 (en) * 2020-07-03 2023-08-17 Ayumi Pharmaceutical Corporation Tablet and method for manufacturing same
BR112023000403A2 (pt) * 2020-07-27 2023-02-07 Daiichi Sankyo Co Ltd Comprimido de desintegração oral, e, método para produzir um comprimido de desintegração oral
WO2022102457A1 (ja) * 2020-11-10 2022-05-19 沢井製薬株式会社 リナグリプチン含有口腔内崩壊錠
CN113181125B (zh) * 2021-04-27 2022-07-19 海南通用三洋药业有限公司 一种西他沙星片剂及其制备方法
CN113332252A (zh) * 2021-06-07 2021-09-03 大桐制药（中国）有限责任公司 一种洛索洛芬钠片的制备方法
CN113244238B (zh) * 2021-06-16 2022-05-20 北京斯利安药业有限公司 含盐酸苯海索和叶酸的口崩片及其制备方法
JP7210794B2 (ja) * 2021-06-16 2023-01-23 日本ジェネリック株式会社 リナグリプチン含有製剤及びリナグリプチン含有口腔内崩壊性錠剤

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE253899T1 (de) * 1994-01-31 2003-11-15 Yamanouchi Pharma Co Ltd Intraoral löslicher formpressling und verfahren zu seiner herstellung
JP4438121B2 (ja) * 1998-04-27 2010-03-24 大正製薬株式会社 口腔内速崩錠及びその製造方法
JP2000273039A (ja) * 1999-01-20 2000-10-03 Taisho Pharmaceut Co Ltd 口腔内崩壊性組成物
JP5584509B2 (ja) * 2003-02-28 2014-09-03 東和薬品株式会社 口腔内崩壊錠剤
JP4551627B2 (ja) * 2003-02-28 2010-09-29 東和薬品株式会社 口腔内崩壊錠剤の製造方法
KR20060033727A (ko) * 2003-06-16 2006-04-19 알러간, 인코포레이티드 메만틴 경구 투여 제형
JP3841804B2 (ja) * 2003-10-15 2006-11-08 富士化学工業株式会社 口腔内速崩壊性錠剤用の組成物
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
CN101420982B (zh) 2006-04-13 2011-11-09 东亚药品株式会社 干式直压速崩片
EP2050448A4 (en) 2006-08-08 2012-01-04 Kissei Pharmaceutical Mouth-dropping tray with masked bitter taste and method of preparation
CN102006861B (zh) 2008-02-13 2012-11-21 大日本住友制药株式会社 口腔崩解片
JP2010070466A (ja) * 2008-09-16 2010-04-02 Kyoto Pharmaceutical Industries Ltd 口腔内崩壊錠
JP5549443B2 (ja) 2009-07-15 2014-07-16 ライオン株式会社 口腔内崩壊錠及びその製造方法
MX2012010648A (es) * 2010-03-31 2012-11-09 Mochida Pharm Co Ltd Preparacion solida de facil dosificacion.
JP5680898B2 (ja) * 2010-08-10 2015-03-04 京都薬品工業株式会社 苦味を抑制した速崩壊錠
EP2810659B1 (en) * 2012-02-03 2017-08-09 Asahi Kasei Kabushiki Kaisha Orally disintegrating tablet containing bitterness-masking granules

Also Published As

Publication number Publication date
CN106913553A (zh) 2017-07-04
JP2017008112A (ja) 2017-01-12
JP2018058910A (ja) 2018-04-12
TWI572371B (zh) 2017-03-01
KR20150003740A (ko) 2015-01-09
BR112014026292A2 (pt) 2017-06-27
JPWO2013161823A1 (ja) 2015-12-24
US9827200B2 (en) 2017-11-28
CA2870868A1 (en) 2013-10-31
JP6545839B2 (ja) 2019-07-17
JP6325627B2 (ja) 2018-05-16
HK1206983A1 (en) 2016-01-22
JP6066351B2 (ja) 2017-01-25
TW201347792A (zh) 2013-12-01
JP7028829B2 (ja) 2022-03-02
BR112014026292B1 (pt) 2022-09-27
ES2694224T3 (es) 2018-12-19
EP2842549A1 (en) 2015-03-04
CN104244930A (zh) 2014-12-24
EP2842549A4 (en) 2015-09-23
KR101943686B1 (ko) 2019-01-29
JP2019151670A (ja) 2019-09-12
EP2842549B1 (en) 2018-08-08
US20150110880A1 (en) 2015-04-23
CA2870868C (en) 2018-02-20
WO2013161823A1 (ja) 2013-10-31

Similar Documents

Publication Publication Date Title
IN2014MN02029A (es)
USD748812S1 (en) Arched cell culture flask
CA140130S (en) Capsule containing washing product
MY162145A (en) Gel composition
MX2012003551A (es) Tabletas transformables via oral.
AU2013328639A8 (en) Fast disintegrating solid dosage form formulation comprising functionalized calcium carbonate and method of their manufacture
MY154063A (en) Stabilized pediatric suspension of carisbamate
MY164904A (en) Tobacco substrate
MX2013006860A (es) Tableta soluble a base de leche con la superficie tratada con carbohidrato.
MX346452B (es) Tableta de multiples capas de desintegracion oral y su elaboracion.
MX2013000791A (es) Particulas de suministro con pluralidad de nucleos.
GB2443793B (en) Product, method of manufacture and use
IN2014DE03239A (es)
PL2870074T3 (pl) Pojemnik na płyny, wykonany z kamienia naturalnego, sposób jego wykonania oraz zastosowanie w sposobie produkcji i magazynowania przeznaczonego do spożycia płynu, zawierającego alkohol
MX360047B (es) Unidad sólida con alto contenido en fexofenadina y su procedimiento de preparación.
WO2014006636A3 (en) Stable compositions of fesoterodine
JP2015129124A5 (es)
MY161968A (en) Granules comprising pyrazosulfron ethyl and pretilachlor
IL235293A (en) A method for producing starch granules and a crumbling tablet in the mouth
ZA201403543B (en) Process for the synthesis of 3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-triene-7-carbonitrile, and application in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
MX2015012311A (es) Proceso para formar un articulo para el cuidado personal.
USD744838S1 (en) Container
WO2010095840A2 (ko) 도네페질 수지 착체
CN204587518U (zh) 药品、保健品、医疗器械包装盒
GEU20101592Y (en) Anber tablet